FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

632 letters match. Newest first.

  1. Vintage Chemical Inc.

    FDA warned Vintage Chemical after an inspection found over-the-counter hand soap and sanitizer made on equipment shared with industrial cleaners.

    High risk
  2. Global Cosmetics Company Limited

    FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  3. C&T Dream Co., Ltd.

    C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.

    High risk
  4. Natco Pharma Limited

    FDA warned Natco Pharma of adulterated drugs after finding dirty equipment and weak investigations at an India plant.

    High risk
  5. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  6. Jiangsu Meifan Biotechnology Co. Ltd.

    FDA cites Jiangsu Meifan Biotechnology for OTC drug manufacturing-rule failures and import alert.

    High risk
  7. FirstCham Co., Ltd.

    FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.

    High risk
  8. Kilitch Healthcare India Limited

    FDA warns Kilitch Healthcare India over insanitary sterile drug manufacturing and falsified environmental monitoring data.

    High risk
  9. Antaria Pty. Ltd.

    FDA warned Antaria Pty. Ltd. about manufacturing quality failures in its active drug ingredient, including poor out-of-specification investigations and testing.

    High risk
  10. Bodywell Natural Skin Care Inc.

    FDA warned Bodywell Natural Skin Care that its OTC hand sanitizer and Dermalere creams were adulterated due to CGMP failures and unapproved drug claims.

    High risk
  11. Betone S.A. de C.V.

    FDA warns Betone S.A. de C.V. over manufacturing violations for OTC antiseptic wipes, including subpotent active and missing glycerin safety tests.

    High risk
  12. Deqing Jiarou Daily Chemical Co., Ltd.

    Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  13. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  14. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  15. Thai Nakorn Patana Co., Ltd.

    FDA warns Thai Nakorn Patana over manufacturing quality violations, including missing identity and strength testing before release of OTC drugs.

    High risk
  16. Bell International Laboratories, Inc.

    Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

    High risk
  17. Colgin, Inc.

    FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.

    High risk
  18. LightEyez Limited

    LightEyez eye drops sold in the U.S. were contaminated with microbes, and FDA cited unapproved new drug claims for its eye drops.

    High risk
  19. Amman Pharmaceutical Industries

    FDA warned Amman Pharmaceutical Industries after a 2023 inspection found sterile drug manufacturing and data integrity failures.

    High risk
  20. EzriCare LLC

    EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.

    High risk
  21. Delsam Pharma LLC

    Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.

    High risk
  22. Sichuan Deebio Pharmaceutical Co. Ltd.

    FDA warns Sichuan Deebio Pharmaceutical over API manufacturing and data-integrity failures.

    High risk
  23. US Chem Labs

    FDA warned US Chem Labs that it sells unapproved and misbranded Semaglutide, Tirzepatide, and Thymalin drugs online.

    High risk
  24. Ningbo Poplar Daily-Use

    FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

    High risk
  25. Madhu Instruments Private Limited

    FDA cites Madhu Instruments in New Delhi for insanitary conditions in sterile drug manufacturing and places it on import alert.

    High risk
  26. QuVa Pharma, Inc.

    FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.

    High risk
  27. Les Importations Herbasanté Inc.

    Canadian contract maker of homeopathic drugs, including children's products, skipped ingredient testing and process validation, FDA says.

    High risk
  28. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  29. S & J International Enterprises Public Company Limited

    FDA cited S & J International Enterprises for CGMP violations, data integrity failures, and limiting access to records during a drug inspection.

    High risk
  30. Mei Lan Thailand Co., Ltd.

    Mei Lan Thailand, an API drug manufacturer, refused an FDA inspection and was placed on Import Alert 55-03.

    High risk
  31. Glicerinas Industriales, S.A. de C.V.

    FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

    High risk
  32. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  33. Woorilife & Health

    Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  34. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  35. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  36. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  37. Omeza LLC

    FDA warned Omeza LLC over mold, insects and animal waste in drug manufacturing areas and unapproved nonprescription drugs.

    High risk
  38. Dextrum Laboratories Inc.

    FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

    High risk
  39. Colonial Dames Company, Ltd

    FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.

    High risk
  40. Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

    FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

    High risk
  41. Novid Group, Inc.

    FDA told Novid Group its OTC nasal spray, novid NASAL SPRAY, is an unapproved new drug and misbranded.

    High risk
  42. Dr. Berne’s Whole Health Products

    Dr. Berne’s MSM eye drops and mist are unapproved new drugs; a tested lot had microbial contamination.

    High risk
  43. Intas Pharmaceuticals Limited

    FDA cited Intas Pharmaceuticals for CGMP violations, including manipulated visual inspection records and inadequate sterile-drug controls.

    High risk
  44. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  45. Cipla Limited

    FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

    High risk
  46. Cerci Kozmetik Ve Otel Ekipmanlari Pazarlama Ic Ve Dis Ticaret Limited Sirketi

    FDA: Turkish OTC drug maker Cerci shipped to the U.S. without finished-product identity and strength testing.

    High risk
  47. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk
  48. National Chemical Laboratories

    National Chemical Laboratories’ OTC topical drugs were adulterated after FDA found manufacturing quality violations, including untested BZK and weak quality oversight.

    High risk
  49. Brenntag Great Lakes, LLC

    Brenntag Great Lakes failed to prevent cross-contamination of OTC hand sanitizer made on equipment shared with industrial chemicals.

    High risk
  50. Elemental Herbs Inc. d/b/a ALL good

    Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.

    High risk